Adaptimmune Therapeutics plc / Fundamentals
Income statement
- Net revenue
€56.07M - Cost of goods sold
€2.91M - Gross profit
€53.16M - SG&A expenses
€72.10M - R&D expenses
€107.90M - EBITDA
-€129.02M - D&A
€9.13M - EBIT
-€141.48M - Interest expenses
€4.88M - EBT
-€143.06M - Tax expenses
€2.21M - Net income
-€146.25M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€9.54M - Changes in working capital
-€23.64M - Operating cash flow
-€163.72M - Capex
€1.45M - Other investing cash flow
-€15.58M - Net investing cash flow
€1.54M - Total cash dividends paid
€0.00 - Issuance of common stock
€1.53M - Debt repayment
€21.43M - Other financing cash flow
-€21.81M - Net financing cash flow
€1.15M - Foreign exchange effects
€0.00 - Net change in cash
-€161.02M - Cash at end of period
€23.93M - Free cash flow
-€162.27M
Balance sheet
- Cash and cash equivalents
€22.45M - Cash and short-term investments
€22.45M - Total receivables
€24.89M - Inventory
€9.83M - Other current assets
€10.12M - Total current assets
€67.30M - Property, plant & equipment
€40.41M - Goodwill
€0.00 - Intangible assets
€3.28M - Long-term investments
€1.48M - Other non-current assets
€80.99K - Total non-current assets
€45.25M - Total assets
€112.55M - Accounts payable
€8.11M - Short-term debt
€7.78M - Other current liabilities
€19.27M - Total current liabilities
€44.38M - Long-term debt
€38.05M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€3.87M - Total non-current liabilities
€129.30M - Total liabilities
€173.68M - Common stock
€1.86M - Retained earnings
-€1.01B - Other equity
-€9.14M - Total equity
-€61.13M - Total liabilities and shareholders' equity
€112.55M
Company information
- Market capitalization
€53.88M - Employees
506 - Enterprise Value
€52.43M
Company ratios
- Gross margin
-
94.8% Much worse than peer group: 341,685,013,465,766,150.0% - EBITDA margin
-
-230.1% Much worse than peer group: 18,115,011,904,870,328.0% - EBIT margin
-
-252.3% Much worse than peer group: 10,126,344,211,836,373.0% - EBT margin
-
-255.1% Much worse than peer group: 18,115,011,904,847,597.0% - Net margin
-
-260.8% Much worse than peer group: 18,115,011,904,847,650.0% - ROE
-
239.2% Much better than peer group: -41.7% - ROA
-
-129.9% Much better than peer group: -305.9% - Asset turnover
-
49.8% Much worse than peer group: 543.4% - FCF margin
-
-294.6% Much worse than peer group: 5,914,810,417,971,176.6% - FCF yield
-306.5% - Efficiency ratio
330.1% - Net sales per employee
-
€110.82K - Net income per employee
-
-€289.04K